
Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Henkel buys FDCA from Avantium NV
From next year, Henkel will buy FDCA to bring environmentally friendly high-performance polyurethane adhesives for electronic applications to market....

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

New EU stakeholder platform to speed up clinical trials
Following strong criticism ahead of the mandatory launch of the CTIS electronic clinical trial reporting portal by the European Medicines Agency...

5 Alarm Bio Ltd raises £500K in seed round
Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, as well as other angel investors participated in Five Alarm Bio’s (FAB) seed round with...

Collaboration to fight cancer
Cancer Research UK and UCB SA have announced to advance two cancer antibodies of the Brussels-based biopharma company to the clinical testing stage....

Abivax SA raises €130m to advance obefazimod to Phase III
Existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point...